V
Vikram Gurtu
Researcher at University of Alberta
Publications - 18
Citations - 1240
Vikram Gurtu is an academic researcher from University of Alberta. The author has contributed to research in topics: Pulmonary hypertension & Internal medicine. The author has an hindex of 11, co-authored 15 publications receiving 1080 citations.
Papers
More filters
Journal ArticleDOI
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
Jayan Nagendran,Stephen L. Archer,Daniel Soliman,Vikram Gurtu,Rohit Moudgil,Alois Haromy,Chantal St. Aubin,Linda Webster,Ivan M. Rebeyka,David B. Ross,Peter E. Light,Jason R.B. Dyck,Evangelos D. Michelakis +12 more
TL;DR: The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.
Journal ArticleDOI
Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients
Evangelos D. Michelakis,Vikram Gurtu,Linda Webster,Gareth Barnes,Geoffrey Watson,Luke Howard,John Cupitt,Ian Paterson,Richard B. Thompson,Kelvin Chow,Declan P. O'Regan,Lan Zhao,John Wharton,David G. Kiely,Adam Kinnaird,Aristeidis E. Boukouris,Christopher W. White,Jayan Nagendran,Darren H. Freed,Stephen J. Wort,J. Simon R. Gibbs,Martin R. Wilkins +21 more
TL;DR: This first-in-human trial of a mitochondria-targeting drug in iPAH demonstrates that PDK is a druggable target and offers hemodynamic improvement in genetically susceptible patients, paving the way for novel precision medicine approaches in this disease.
Journal ArticleDOI
Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans.
Roxane Paulin,Peter Dromparis,Gopinath Sutendra,Vikram Gurtu,Sotirios Zervopoulos,Lyndsay Bowers,Alois Haromy,Linda Webster,Steeve Provencher,Sébastien Bonnet,Evangelos D. Michelakis +10 more
TL;DR: A loss-of-function SIRT3 polymorphism, linked to metabolic syndrome, is associated with PAH in an unbiased cohort of 162 patients and controls, and may facilitate biomarker and therapeutic discovery programs in PAH.
Journal ArticleDOI
A miR-208–Mef2 Axis Drives the Decompensation of Right Ventricular Function in Pulmonary Hypertension
Roxane Paulin,Gopinath Sutendra,Vikram Gurtu,Peter Dromparis,Alois Haromy,Steeve Provencher,Sébastien Bonnet,Evangelos D. Michelakis +7 more
TL;DR: An RV-specific mechanism for heart failure is described, which could potentially lead to new biomarkers and therapeutic targets, and mechanistic in vitro experiments using neonatal and adult RV cardiomyocytes showed that miR-208 inhibition activates the complex mediator of transcription 13/nuclear receptor corepressor 1 axis, which promotes Mef2 inhibition.
Journal ArticleDOI
A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted.
Jayan Nagendran,Vikram Gurtu,David Z. Fu,Jason R.B. Dyck,Al Haromy,David B. Ross,Ivan M. Rebeyka,Evangelos D. Michelakis +7 more
TL;DR: The dynamic changes in mitochondrial membrane potential during right ventricular hypertrophy are chamber-specific, associated with activation of NFAT, and can be pharmacologically reversed leading to improved contractility.